UroGen Pharma Ltd.
URGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $90,398 | $82,713 | $64,357 | $48,042 |
| % Growth | 9.3% | 28.5% | 34% | – |
| Cost of Goods Sold | $8,881 | $9,361 | $7,654 | $5,157 |
| Gross Profit | $81,517 | $73,352 | $56,703 | $42,885 |
| % Margin | 90.2% | 88.7% | 88.1% | 89.3% |
| R&D Expenses | $57,145 | $45,614 | $52,906 | $47,642 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $93,274 | $82,838 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $121,154 | $0 | $0 | $87,535 |
| Operating Expenses | $178,299 | $138,888 | $135,744 | $135,177 |
| Operating Income | -$96,782 | -$65,536 | -$79,041 | -$92,292 |
| % Margin | -107.1% | -79.2% | -122.8% | -192.1% |
| Other Income/Exp. Net | -$27,260 | -$32,788 | -$28,987 | -$17,079 |
| Pre-Tax Income | -$124,042 | -$98,324 | -$108,028 | -$109,371 |
| Tax Expense | $2,832 | $3,920 | $1,755 | $1,449 |
| Net Income | -$126,874 | -$102,244 | -$109,783 | -$110,820 |
| % Margin | -140.4% | -123.6% | -170.6% | -230.7% |
| EPS | -2.96 | -3.55 | -4.79 | -4.96 |
| % Growth | 16.6% | 25.9% | 3.4% | – |
| EPS Diluted | -2.96 | -3.55 | -4.79 | -4.96 |
| Weighted Avg Shares Out | 42,877 | 28,834 | 22,807 | 22,347 |
| Weighted Avg Shares Out Dil | 42,877 | 28,834 | 22,807 | 22,347 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,901 | $2,641 | $938 | $365 |
| Interest Expense | $12,521 | $14,715 | $8,438 | $0 |
| Depreciation & Amortization | $329 | $1,705 | $1,817 | $831 |
| EBITDA | -$95,353 | -$60,352 | -$76,214 | -$91,461 |
| % Margin | -105.5% | -73% | -118.4% | -190.4% |